How US Tariffs Are Reshaping UK Pharma Markets

The global pharmaceutical landscape is undergoing a dramatic transformation, with UK pharma feeling the squeeze from US pricing reforms and tariff threats. This episode dives deep into how the 2022 US Inflation Reduction Act has created a domino effect across international markets, forcing companies to make tough strategic choices about pricing and market access.

When Eli Lilly temporarily suspended shipments of its blockbuster GLP-1 drug Manjaro to the UK in August, it wasn't due to production challenges—it was a deliberate pricing strategy. With Manjaro projected to exceed $5 billion in sales by 2026, the signal to the UK's National Health Service was clear: current reimbursement models aren't sustainable in this new global pricing reality. The situation has deteriorated to the point where Novartis UK's managing director recently declared the country "largely uninvestable" for pharmaceutical innovation.

At the heart of this crisis lies the UK's Voluntary Scheme for Branded Medicines Pricing and Access, which requires pharma companies to reimburse approximately 27% of net sales to the NHS—the highest rate in Europe. Add Brexit complications that have increased market launch times by 12-16 weeks and compliance costs by 20%, and you have a perfect storm threatening patient access to innovative therapies.

For pharma brand managers, access teams, and innovation leaders, this new landscape demands strategy recalibration. Global launch sequencing will increasingly prioritize markets with predictable pricing environments, while digital companion tools that demonstrate improved outcomes will become essential in negotiating value-based agreements. The future belongs to companies that can think globally while navigating local market complexities, leveraging data to demonstrate value, and maintaining transparent communication with patients caught in the middle of these pricing battles.

Curious about how these global pricing shifts will affect patient access and the future of pharmaceutical innovation? Subscribe to Postscripts for ongoing insights into the changing landscape of healthcare delivery and pharmaceutical strategy.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.